期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
miR-635靶向调控MYL6B抑制非小细胞肺癌转移
1
作者 夏炳辉 张振山 +3 位作者 姚天宇 葛凤月 鄢凤梅 孙金鹏 《生物技术》 2025年第3期358-363,370,共7页
[目的]探究miR-635与MYL6B对非小细胞肺癌H1650细胞转移活性的影响。[方法]采用实时荧光定量PCR方法检测miR-635的表达水平,通过蛋白免疫印迹方法检测非小细胞肺癌组织中MYL6B的表达情况。将H1650细胞株随机分为4组:miR NC组、miR-635 m... [目的]探究miR-635与MYL6B对非小细胞肺癌H1650细胞转移活性的影响。[方法]采用实时荧光定量PCR方法检测miR-635的表达水平,通过蛋白免疫印迹方法检测非小细胞肺癌组织中MYL6B的表达情况。将H1650细胞株随机分为4组:miR NC组、miR-635 mimic组、si NC组与si MYL6B组。蛋白免疫印迹检测MYL6B蛋白的表达水平,采用EdU染色分析H1650细胞的增殖能力,细胞划痕实验分析H1650细胞的侵袭能力,流式细胞仪检测H1650细胞凋亡率,生物信息学方法预测miR-635与MYL6B在H1650细胞中的结合区域,双荧光素酶报告基因实验分析miR-635与MYL6B在H1650细胞中的的靶向关系。[结果]非小细胞肺癌组织中miR-635表达水平降低(0.79±0.05 vs 0.31±0.07),MYL6B表达增加(0.18±0.02 vs 0.82±0.09);miR-635能够靶向抑制MYL6B的活性(0.98±0.08 vs 0.27±0.03);miR-635 mimic或si MYL6B均能抑制H1650细胞的生长与迁移能力,并能促进H1650细胞凋亡(8.08%±1.72%vs 33.97%±2.08%vs 7.92%±1.27%vs 33.11%±2.17%,P<0.05)。[结论]MYL6B在非小细胞肺癌组织高表达,而miR-635低表达。MYL6B是miR-635的直接靶点,miR-635对非小细胞肺癌H1650细胞转移活性的抑制作用与调控MYL6B相关。 展开更多
关键词 miR-635 非小细胞肺癌 myl6b 转移 侵袭 H1650 增殖 凋亡
原文传递
Study on the expression and prognostic relationship of MYL6B in liver cancer based on bioinformatics
2
作者 Hai-Bing Lv Qing-Yun Wu +4 位作者 Yu-Jiao Zhang Sheng-Wei Quan Ning Ma Yu-Qing Dai Yan Sun 《World Journal of Clinical Oncology》 2024年第9期1188-1197,共10页
BACKGROUND Primary liver cancer is a prevalent and deadly cancer type.Despite treatment advances,prognosis remains poor,with high recurrence rates.Early detection is crucial but challenging due to the disease’s insid... BACKGROUND Primary liver cancer is a prevalent and deadly cancer type.Despite treatment advances,prognosis remains poor,with high recurrence rates.Early detection is crucial but challenging due to the disease’s insidious nature.Myosin proteins play significant roles in cancer development,influencing cell migration,invasion,and tumor suppression.MYL6B,a myosin light chain,is involved in various cellular processes and has been associated with poor prognosis in colorectal adenocarcinoma and potential as a biomarker in breast cancer.AIM To investigate the expression of MYL6B in liver hepatocellular carcinoma(LIHC)and its impact on prognosis and potential mechanisms of action using bioinformatics methods.METHODS The expression of MYL6B in pan-cancer and normal tissues was analyzed using the gene expression profiling interactive analysis 2 and tumor immune estimation resource databases.The expression level of MYL6B in LIHC tissues and its relationship with prognosis were analyzed,immunohistochemical analysis of MYL6B and its effect on immune cell infiltration,and the protein network were further studied.RESULTS MYL6B was highly expressed in diffuse large b-cell lymphoma,LIHC,pancreatic adenocarcinoma,skin cutaneous melanoma,thymoma,uterine corpus endometrial carcinoma,uterine carcinosarcoma,and lowly expressed in kidney chromophobe,acute myeloid leukemia,testicular germ cell tumors.The expression level of MYL6B was significantly different between cancer and normal tissues.It had a significant impact on both overall survival and disease-free survival.MYL6B is highly expressed in hepatocellular carcinoma and its expression level increases with cancer progression.High MYL6B expression is associated with poor prognosis in terms of overall survival and recurrence-free survival.The immunohistochemical level of MYL6B is high in hepatocellular carcinoma tissues,and MYL6B has a high level of immune infiltration inflammation.In protein network analysis,MYL6B is correlated with MYL2,MYL6,MYL9,MYLK4,MYLK2,MYL12A,MYL12B,MYH11,MYH9 and MYH10.CONCLUSION The expression level of MYL6B in LIHC was significantly higher than in normal liver tissues,and it was correlated with the degree of differentiation survival rate,and immune infiltration.MYL6B is a potential target for LIHC treatment. 展开更多
关键词 myl6b Liver cancer BIOINFORMATICS PROGNOSIS EXPRESSION
暂未订购
上一页 1 下一页 到第
使用帮助 返回顶部